HOLX to Feature Innovative Products - Analyst Blog
26 3월 2013 - 12:00AM
Zacks
Women’s healthcare major
Hologic Inc. (HOLX) will showcase the benefits of
its leading-edge 3D mammography systems at the 23rd Annual National
Interdisciplinary Breast Cancer Conference in Las Vegas hosted by
the National Consortium of Breast Cancer (NCBC).
The company will resort to a mobile coach tour at the conference to
expand its reach. The innovative initiative dubbed ‘3D Technology:
A More Accurate Mammogram’ should publicize the clinical benefits
of its 3D mammography systems to the medical community and target
population. According to the company, a mobile configuration will
increase the scope of its critical screening tool for women who
otherwise do not have the access to technically advanced systems
for breast imaging.
Results from clinical studies demonstrate the efficacy of Hologic’s
well-regarded technology as its 3D mammography in conjunction with
the routine 2D imaging improves detection of cancer. It also
decreases the need for callbacks as shown by the findings from the
study titled Comparison of Digital Mammography Alone and
Digital Mammography Plus Tomosynthesis in a Population-based
Screening Program. The increase in detection rate and decrease
in the need for callbacks is crucial for women with restricted
access to annual screening mammography.
Although mortality rate from breast cancer declined 31% since 1990
on the heels of higher detection rates with mammographic screening,
more than 40% American women still undergo only regular screening.
This is mainly due to lack of easy access for these women.
Hologic’s mobile mammography addresses this issue by enabling
point-of-care mammographic screening for women.
Apart from its 3D mammography systems, the company will also
display its Advanced Body Composition Assessment package for the
osteoporosis assessment system, new tomosynthesis biopsy option to
be used on the Affirm biopsy guidance system. Hologic also plans to
showcase its CE marked synthesized 2D (C-View) images.
Offering a wide range of products, Hologic is arguably an industry
leader in the field of women’s health. Going forward, we are
optimistic about increasing uptake of the company’s technically
advanced solutions.
The stock carries a Zacks Rank #3 (Hold). Although we remain on the
sidelines for Hologic, we believe that other medical stocks such as
Abaxis (ABAX), Conceptus (CPTS)
and Cyberonics (CYBX) are likely to do well. These
stocks carry a Zacks Rank #2 (Buy) each.
ABAXIS INC (ABAX): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Abaxis, Inc. (delisted) (나스닥)의 실시간 뉴스: 최근 기사 0
More Abaxis, Inc. (MM) News Articles